S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
Is This The End of Capitalism? (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
Is This The End of Capitalism? (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
Is This The End of Capitalism? (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
Is This The End of Capitalism? (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
NASDAQ:NVCR

NovoCure - NVCR Earnings Date, Estimates & Call Transcripts

$90.90
+0.85 (+0.94%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$88.72
$91.69
50-Day Range
$67.94
$118.81
52-Week Range
$56.39
$120.03
Volume
542,608 shs
Average Volume
1.70 million shs
Market Capitalization
$9.54 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$110.13

Earnings Summary

Upcoming
Earnings Date
Feb. 23Confirmed
Actual EPS
(Oct. 27)
-$0.25 Beat By $0.05
Consensus EPS
(Oct. 27)
-$0.30
Last Year's Q4 EPS
(10/28/2021)
-$0.13
Skip Charts & View Estimated and Actual Earnings Data

NVCR Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

NVCR Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

NovoCure Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20231$0.00$0.00$0.00 
Q2 20232($0.21)$0.01($0.10) 
Q3 20232($0.21)$0.03($0.09) 
Q4 20232($0.21)$0.05($0.08) 
FY 20237($0.63)$0.09 ($0.27)

NVCR Earnings Date and Information

NovoCure last posted its quarterly earnings data on October 27th, 2022. The medical equipment provider reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.05. The company earned $131 million during the quarter, compared to the consensus estimate of $134.83 million. NovoCure has generated ($0.77) earnings per share over the last year (($0.77) diluted earnings per share). Earnings for NovoCure are expected to decrease in the coming year, from ($0.85) to ($1.15) per share. NovoCure has confirmed that its next quarterly earnings report will be published on Thursday, February 23rd, 2023. NovoCure will be holding an earnings conference call on Thursday, February 23rd at 8:00 AM Eastern. Interested parties can register for or listen to the call..

NovoCure Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
2/23/2023
(Confirmed)
 ($0.32)       
10/27/2022Q3 2022($0.30)($0.25)+$0.05($0.25)$134.83 million$131.00 million
7/28/2022Q2 2022($0.14)($0.23)($0.09)($0.23)$135.13 million$140.90 million    
4/28/2022Q1 2022($0.17)($0.04)+$0.13($0.04)$134.29 million$137.50 million      
2/24/2022Q4 2021($0.10)($0.25)($0.15)($0.25)$134.49 million$133.20 million    
10/28/20219/30/2021($0.06)($0.13)($0.07)($0.13)$141.22 million$133.61 million    
7/29/20216/30/2021$0.02($0.14)($0.16)($0.14)$141.50 million$133.52 million      
4/29/20213/31/2021$0.02($0.04)($0.06)($0.04)$136.54 million$134.70 million    
2/25/202112/31/2020$0.13$0.04($0.09)$0.04$143.49 million$144.00 million    
10/29/20209/30/2020$0.04$0.09+$0.05$0.09$120.02 million$132.70 million    
7/30/20206/30/2020$0.01$0.02+$0.01$0.02$105.96 million$115.90 million    
4/30/20203/31/2020$0.03$0.04+$0.01$0.04$102.10 million$101.83 million    
2/27/202012/31/2019$0.02$0.04+$0.02$0.04$99.10 million$99.23 million    
10/31/2019Q3($0.05)$0.02+$0.07$0.02$87.12 million$92.06 million  
7/25/2019Q2($0.07)($0.01)+$0.06($0.01)$78.98 million$86.70 million  
5/2/20193/31/2019($0.13)($0.13)($0.13)$72.85 million$73.31 million
2/28/2019Q4 2018($0.15)($0.17)($0.02)($0.17)$69.67 million
10/25/20189/30/2018($0.15)($0.13)+$0.02($0.13)$65.61 million$64.76 million
7/26/2018Q2($0.16)($0.17)($0.01)($0.17)$59.53 million$61.50 million
4/26/20183/31/2018($0.13)($0.23)($0.10)($0.23)$57.13 million$52.13 million
2/22/2018Before Market($0.14)($0.12)+$0.02($0.12)$53.17 million$53.66 million  
10/26/20179/30/2017($0.20)($0.13)+$0.07($0.13)$43.45 million$50.10 million
7/27/20176/30/2017($0.23)($0.24)($0.01)($0.24)$42.20 million$38.38 million
4/27/20173/31/2017($0.25)($0.21)+$0.04($0.21)$39.46 million$34.88 million
2/23/2017Q416($0.39)($0.26)+$0.13($0.26)$26.95 million$30.20 million
11/2/2016Q3 2016($0.42)($0.39)+$0.03($0.39)$21.65 million$21.67 million
7/28/2016Q216($0.37)($0.48)($0.11)($0.48)$15.90 million$17.90 million  
5/9/2016Q116($0.33)($0.42)($0.09)($0.42)$23.65 million$13.10 million
2/29/2016Q4 2015($0.32)$2.54+$2.86$2.54$17.85 million$12.38 million
10/26/2015Q315($2.09)($2.09)($2.09)$4.37 million$8.95 million












NovoCure Earnings - Frequently Asked Questions

When is NovoCure's earnings date?

NovoCure has confirmed that its next quarterly earnings data will be published on Thursday, February 23rd, 2023. Learn more on NVCR's earnings history.

Did NovoCure beat their earnings estimates last quarter?

In the previous quarter, NovoCure (NASDAQ:NVCR) reported ($0.25) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.30) by $0.05. Learn more on analysts' earnings estimate vs. NVCR's actual earnings.

How much revenue does NovoCure generate each year?

NovoCure (NASDAQ:NVCR) has a recorded annual revenue of $535.03 million.

How much profit does NovoCure generate each year?

NovoCure (NASDAQ:NVCR) has a recorded net income of -$58.35 million. NVCR has generated -$0.77 earnings per share over the last four quarters.

What is NovoCure's EPS forecast for next year?

NovoCure's earnings are expected to decrease from ($0.85) per share to ($1.15) per share in the next year.

More Earnings Resources from MarketBeat

Upcoming Earnings:
This page (NASDAQ:NVCR) was last updated on 1/28/2023 by MarketBeat.com Staff